Navigation Links
Consumer Advocates Support Patent Office on Stem Cell Patent Rejection
Date:11/5/2007

SANTA MONICA, Calif., Nov. 5 /PRNewswire-USNewswire/ -- Amended stem cell patent claims submitted by the Wisconsin Alumni Research Foundation don't overcome the U.S. Patent Office Examiner's rejections and the claims remain unpatentable, two consumer groups said today.

In formal comments filed Friday the Foundation for Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation (PUBPAT) asked that the rejections first issued on March 30 by the U.S. PTO be made final.

"Stem cell science would be best served if WARF simply withdrew their overreaching claims," said John M. Simpson, FTCR's stem cell project director.

In July 2006 the FTCR and PUBPAT challenged three patents held by WARF because they are hindering stem cell research. Stem Cell Scientist Dr. Jeanne Loring supported the challenge, which led to the rejection of all claims of all three patents in March.

In June WARF offered counter arguments and then in October filed what it described as "technical amendments" to the patent claims.

"Upon review, however, none of those amendments are sufficient to overcome the Examiner's rejections," wrote Daniel B. Ravicher, PUBPAT's executive director. "As such, the claims remain unpatentable."

Read the filing here: http://www.consumerwatchdog.org/resources/913SuppComments.pdf

Four internationally known stem cell scientists, Loring of the Burnham Institute for Medical Research, soon to join the Scripps Research Institute; Dr. Douglas Melton of Harvard University; Dr. Alan Trounson of Monash University in Australia, soon to take over as president of the California Institute for Regenerative Medicine; and Dr. Chad Cowan of Harvard University filed declarations supporting the consumer groups and the PTO's earlier finding that the work done by Dr. James Thomson does not deserve a patent.

WARF holds three stem cell patents, numbers '780, '806 and '913, based on work done by Thomson. The rules applicable to the '913 case under a so-called "inter partes" re-examination allow the challengers to comment on WARF's responses in that proceeding.

The two earlier patents are undergoing "ex parte" re-examination and those rules do not allow formal comment from FTCR and PUBPAT. Nonetheless, the points made by FTCR and PUBPAT in the '913 case are relevant to the other two.

Since the groups filed their challenge, WARF has substantially eased licensing requirements for stem cell researchers

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at: http://www.ConsumerWatchdog.org and http://www.oilwatchdog.org.

The Public Patent Foundation is a not-for-profit legal services organization that represents the public's interests against the harms caused by the patent system, particularly the harms caused by wrongly issued patents and unsound patent policy. For more information, visit us on the web at http://www.pubpat.org.


'/>"/>
SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. EntreMed Raises $20 Million to Support Clinical Development Program
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
8. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
9. Data Support use of SuperGens CLIMB Technology in Lead Development and Optimization
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the ... Cardiology Devices segment is likely to create absolute $ opportunity ... over 2017. By the end of 2027, Cardiology Devices segment ... 700 Mn, expanding at a CAGR of 18.4% over the ... Asia Pacific reprocessed medical devices market in terms ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):